Osteolysis and pain due to experimental bone metastases are improved by treatment with rapamycin

Dareen M. Abdelaziz, Laura S. Stone, Svetlana V. Komarova

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

In advanced breast cancer, bone metastases occur in 70 % of patients. Managing the devastating pain associated with the disease is difficult. Rapamycin is an immunomodulatory drug that targets the mammalian target of rapamycin pathway. Rapamycin has been shown to decrease osteolysis associated with metastatic breast cancer in pre-clinical models and to reduce pain in inflammatory and neuropathic models. The aim of this study was to evaluate the effectiveness of rapamycin in reducing pain associated with experimental osteolytic metastases. Bone cancer was induced by intra-tibial injections of murine mammary carcinoma cells (4T1) in immunocompetent BALB/c mice and treated intraperitoneally for up to 5 weeks with vehicle, rapamycin or pamidronate (a bisphosphonate currently used to reduce bone loss in bone cancer patients). The control group received intra-tibial injection with saline (sham) and was treated with vehicle intraperitoneally. Cancer-induced osteolysis was observed histologically and radiographically 2-3 weeks following cancer inoculation and gradually increased with time. Measures of evoked nociceptive behaviors including sensitivity to mechanical, thermal, and cold stimuli and spontaneous nociceptive behaviors (limping, guarding) were evaluated. Significant hypersensitivity to sensory stimuli developed in cancer-bearing mice compared to sham 3 weeks following inoculation. Rapamycin decreased or delayed the development of cancer-induced mechanical, heat, and cold hypersensitivity, while pamidronate reduced heat and cold hypersensitivity. Both rapamycin and pamidronate had a partial protective effect on the spontaneous nociceptive behaviors, limping and guarding. Our data suggest that rapamycin may have efficacy in the management of pain associated with metastatic breast cancer.

Original languageEnglish (US)
Pages (from-to)227-237
Number of pages11
JournalBreast Cancer Research and Treatment
Volume143
Issue number2
DOIs
StatePublished - Jan 2014

Bibliographical note

Funding Information:
Acknowledgments We thank Dr. Peter Siegel for providing the 4T1 cells, Drs. Magali Millecamps and Osama Hussein for teaching and supporting the pilot experiment, Drs. Monzur Murshed and Frank Rauch for advice on histomorphometric analysis and McGill University undergraduate students Anita Ramachandran, Jingwen Chen, Katia Fox, and Robert Samberg for helping with experiments. This study was supported by the Cancer Research Society/Quebec Breast Cancer Foundation grant to LSS and SVK. DMA is supported by the Ministry of Higher Education, Egypt. SVK holds Canada Research Chair in Osteoclast Biology.

Keywords

  • 4T1
  • Breast cancer metastases
  • Pamidronate
  • Rapamycin
  • Tibial injection model
  • mTOR

Fingerprint Dive into the research topics of 'Osteolysis and pain due to experimental bone metastases are improved by treatment with rapamycin'. Together they form a unique fingerprint.

Cite this